8,030
+0.88%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmicell Co
Its shares trade on KRX under the ticker 005690.KS. It has been listed since 20 May 1988. In the fiscal year to 31 December 2025, it reported revenue of ₩114.06bn and net income of ₩40.29bn. At that date it held total assets of ₩157.17bn and shareholders' equity of ₩123.88bn.
Pharmicell Co., Ltd. is engaged in the development of stem cell based pharmaceuticals and technologies. The company is headquartered in Seoul, Seoul. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. The company also provides steam cell storage services, and mesenchymal stem cells (MSCs) used for research areas and others. In addition, the Company engages in the fashion business, which provides women’s and men’s apparels under the brand names of Religion and Day. On March 31, 2013, the Company merged with its wholly owned subsidiary, mainly engaged in the manufacture and sale of medicines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 May 1988
- Employees
- 134
- Website
- pharmicell.com ↗
Leadership
Pay as last reported
- Mr. Hyeon Su KimChief Executive Officer, Director, since 2009₩1.07bn
- Mr. Seong Nyeon KimVice President
- Mr. Gwang Rae KimAssistant Managing Director
- Mr. Jae Hak KimAssistant Managing Director
- Mr. Su Chan KimAssistant Managing Director
- Mr. Gil Su JungDirector
- Mr. Byeong Mu YooOther Non-Executive Director
- Mr. Tae Se GwonNon-Executive Independent Director
- Mr. Seung Gyeong HanNon-Executive Independent Director
- Mr. Hui Cheol JungNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmicell Co Ltd has a biopharmaceutical business focused on stem cell therapeutic drugs and stem cell-based cosmetics.
- The company provides mesenchymal stem cells (MSCs) for research purposes and stem cell storage services.
- Pharmicell Co Ltd is headquartered in Seoul, South Korea, with 134 employees.
Weaknesses
- The company's biopharmaceutical business includes stem cell-based cosmetics, which may face regulatory challenges in the Health Care sector.
- Pharmicell Co Ltd has a recent merger with a wholly owned subsidiary engaged in medicine manufacturing as of March 31, 2013.
- The company's operations include a fashion business under the brand names Religion and Day, which is unrelated to its core biotechnology sector.
Opportunities
- Pharmicell Co Ltd can expand its stem cell therapeutic drugs into new markets within the Health Care sector.
- The company's stem cell storage services could grow with increasing demand for regenerative medicine.
- Pharmicell Co Ltd's focus on mesenchymal stem cells (MSCs) for research may attract partnerships in the biotechnology industry.
Threats
- Pharmicell Co Ltd faces potential regulatory hurdles for stem cell-based cosmetics in the Health Care sector.
- The fashion business under Religion and Day may distract from the company's primary biotechnology focus.
- The company's reliance on stem cell technologies could be impacted by advancements in alternative medical treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.